Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Opioid Response Policy topic
No spam. Unsubscribe anytime.
Policy committee reviews opioid-antagonist policy; updates replace 'naloxone' with statutory term
Summary
During a first reading, the William Penn School District policy committee reviewed revisions to Policy 823 to align terminology with a January 2022 statute and clarified staff roles and training requirements from the Pennsylvania Department of Health.
The William Penn School District policy committee held a first reading of revisions to Policy 823 (Opioid Antagonist) at its Oct. 2, 2025, meeting. Harris, a district staff member, said the draft updates the district’s language to match state law and clarifies who is responsible for custody and administration of opioid antagonist medication.
“The term that was previously used was naloxone, and we need to change that to opioid antagonist,” Harris said, referring to alignment with legislative terminology adopted in January 2022. He said the draft also “further clarifies the role of different school staff in managing and maintaining that medication.”
Harris said staff responsible for custody of the medication should “receive and complete the necessary training, from the PA Department of Health about the use, related overdoses, and ensuring prompt medical attention is provided.” Committee discussion focused on terminology, staff training and recordkeeping; no formal vote was recorded on Policy 823 during the meeting. The item remains at first reading under the district’s policy-adoption schedule.
The committee concluded its meeting and set its next session for Nov. 6, 2025.
